Hou Wanting, Tang Qiulin, Bi Feng
Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P.R.China;Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610041, P.R.China.
Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610041, P.R.China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2019 Apr 25;36(2):267-273. doi: 10.7507/1001-5515.201801057.
To evaluate the differential expression profiles of the lncRNAs, miRNAs, mRNAs and ceRNAs, and their implication in the prognosis in clear cell renal cell carcinoma (CCRCC), the large sample genomics analysis technologies were used in this study. The RNA and miRNA sequencing data of CCRCC were obtained from The Cancer Genome Atlas (TCGA) database, and R software was used for gene expression analysis and survival analysis. Cytoscape software was used to construct the ceRNA network. The results showed that a total of 1 570 lncRNAs, 54 miRNAs, and 17 mRNAs were differentially expressed in CCRCC, and most of their expression levels were up-regulated (false discovery rate < 0.01 and absolute log fold change > 2). The ceRNA regulatory network showed the interaction between 89 differentially expressed lncRNAs and 9 differentially expressed miRNAs. Further survival analysis revealed that 38 lncRNAs (including COL18A1-AS1, TCL6, LINC00475, UCA1, WT1-AS, HOTTIP, PVT1, etc.) and 2 miRNAs (including miR-21 and miR-155) were correlated with the overall survival time of CCRCC ( < 0.05). Together, this study provided us several new evidences for the targeted therapy and prognosis assessment of CCRCC.
为了评估长链非编码RNA(lncRNA)、微小RNA(miRNA)、信使RNA(mRNA)和竞争性内源性RNA(ceRNA)的差异表达谱及其在透明细胞肾细胞癌(CCRCC)预后中的意义,本研究采用了大样本基因组分析技术。CCRCC的RNA和miRNA测序数据来自癌症基因组图谱(TCGA)数据库,R软件用于基因表达分析和生存分析。Cytoscape软件用于构建ceRNA网络。结果显示,共有1570个lncRNA、54个miRNA和17个mRNA在CCRCC中差异表达,且它们的表达水平大多上调(错误发现率<0.01且绝对对数倍变化>2)。ceRNA调控网络显示了89个差异表达的lncRNA与9个差异表达的miRNA之间的相互作用。进一步的生存分析表明,38个lncRNA(包括COL18A1-AS1、TCL6、LINC00475、UCA1、WT1-AS、HOTTIP、PVT1等)和2个miRNA(包括miR-21和miR-155)与CCRCC的总生存时间相关(<0.05)。总之,本研究为CCRCC的靶向治疗和预后评估提供了一些新的证据。